Literature DB >> 9693262

Apolipoprotein E polymorphism is not associated with longevity or disability in a sample of Italian octo- and nonagenarians.

G Bader1, G Zuliani, G M Kostner, R Fellin.   

Abstract

BACKGROUND: Apolipoprotein E (apo E) is a protein associated with plasma lipoproteins. Apo E polymorphism has been related to significant modifications of lipoprotein profile, as well as to the incidence of different pathologies including cardiovascular disease, Alzheimer's disease, and vascular dementia. Furthermore, it was proposed that apo E polymorphism might be involved in the aging selection process.
OBJECTIVE: The purposes of the present study were the following: (1) to evaluate apo E polymorphism in 'successful' and 'unsuccessful' aging, defined as the absence or presence of disability and severe chronic diseases (mainly cardiovascular disease and dementia), respectively; (2) to evaluate the impact of apo E polymorphism on plasma lipids in very old individuals free of or affected by disability.
METHODS: 253 Italian subjects including 100 free-living healthy octo- and nonagenarians, 62 disabled octo- and nonagenarians, and 91 healthy adult controls, all matched for origin were studied. Apo E phenotypes were determined by PhastSystem (Pharmacia). Lipoprotein parameters (total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, lipoprotein (a), and apoprotein A-I and B) were measured by standardized methods. ADL were evaluated by the Katz index.
RESULTS: The frequency of sigma2, sigma3, and sigma4 alleles was 0.062, 0.887, and 0.051 respectively in the entire sample; no differences in alleles distribution were found between the three groups. When the subjects were divided according to the E type (E2 type: E2/E2 and E2/E3; E3 type: E3/E3; E4 type: E3/E4 and E4/E4), no differences in lipoprotein parameters emerged, but a trend toward higher total and LDL-cholesterol from the E2 to the E4 type was observed. The sigma4 allele had a raising effect, while sigma2 had a lowering effect on total cholesterol levels, but these effects were much less profound in the disabled octo- and nonagenarians.
CONCLUSIONS: We conclude that (1) the frequency of the sigma4 allele is very low in this sample of subjects from central Italy; (2) no differences emerged in sigma4 distribution between healthy and disabled octo- and nonagenarians, and adult controls; the very low frequency of sigma4 allele might contribute to this finding; (3) our data do not support the hypothesis of a possible association between apo E polymorphism and longevity or disability in this population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9693262     DOI: 10.1159/000022030

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  16 in total

1.  Successful aging shows linkage to chromosomes 6, 7, and 14 in the Amish.

Authors:  Digna R Velez Edwards; John R Gilbert; Lan Jiang; Paul J Gallins; Laura Caywood; Marilyn Creason; Denise Fuzzell; Clare Knebusch; Charles E Jackson; Margaret A Pericak-Vance; Jonathan L Haines; William K Scott
Journal:  Ann Hum Genet       Date:  2011-07       Impact factor: 1.670

2.  The apolipoprotein E e4 polymorphism is strongly associated with poor mobility performance test results but not self-reported limitation in older people.

Authors:  David Melzer; M G Dik; Gerard J van Kamp; Cees Jonker; Dorly J Deeg
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-10       Impact factor: 6.053

3.  Role of APOE genotype in gait decline and disability in aging.

Authors:  Joe Verghese; Roee Holtzer; Cuiling Wang; Mindy J Katz; Nir Barzilai; Richard B Lipton
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-07-31       Impact factor: 6.053

4.  Contribution of genetic polymorphisms on functional status at very old age: a gene-based analysis of 38 genes (311 SNPs) in the oxidative stress pathway.

Authors:  S Dato; M Soerensen; V Lagani; A Montesanto; G Passarino; K Christensen; Q Tan; L Christiansen
Journal:  Exp Gerontol       Date:  2014-01-22       Impact factor: 4.032

5.  Apolipoprotein E and familial longevity.

Authors:  Nicole Schupf; Sandra Barral; Thomas Perls; Anne Newman; Kaare Christensen; Bharat Thyagarajan; Michael Province; Winifred K Rossi; Richard Mayeux
Journal:  Neurobiol Aging       Date:  2012-10-05       Impact factor: 4.673

6.  Apolipoprotein E genotype and risk of developing physical limitations in elderly people.

Authors:  Tzuo-Yun Lan; Wen-Chiung Chang; Tsuo-Hung Lan; Baai-Shyun Hurng
Journal:  J Am Geriatr Soc       Date:  2009-07       Impact factor: 5.562

7.  Apolipoprotein E genotype frequency patterns in aged Danes as revealed by logistic regression models.

Authors:  Qihua Tan; Lene Christiansen; Kaare Christensen; Torben A Kruse; Lise Bathum
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

8.  Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men.

Authors:  Alexander M Kulminski; Svetlana V Ukraintseva; Konstantin G Arbeev; Kenneth G Manton; Junko Oshima; George M Martin; Dora Il'yasova; Anatoli I Yashin
Journal:  J Am Geriatr Soc       Date:  2008-01-04       Impact factor: 5.562

9.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

10.  Association between APOE epsilon 2/epsilon 3/epsilon 4 polymorphism and disability severity in a national long-term care survey sample.

Authors:  Alexander Kulminski; Svetlana V Ukraintseva; Konstantin G Arbeev; Kenneth G Manton; Junko Oshima; George M Martin; Anatoli I Yashin
Journal:  Age Ageing       Date:  2008-02-04       Impact factor: 10.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.